Information about the Moderna COVID-19 Vaccine
2 shots, one month (28 days) apart
Moderna's vaccine was shown to be 94.1% effective in preventing laboratory-confirmed COVID-19 cases in people who received two doses and who had no evidence of previous infections.
General information
Name: mRNA-1273
Manufacturer: ModernaTX, Inc.
Vaccine type: mRNA
Number of injections: 2 injections one month (28 days) apart
Mode of administration: injection into the muscle of the upper arm
Does not contain: Eggs, Preservatives, Latex.
Who should get vaccinated?
Moderna's vaccine is recommended for people 18 years of age or older
Who should not get vaccinated?
If you have had a severe allergic reaction, also known as anaphylaxis, to any of the ingredients in Moderna's vaccine, you should not get vaccinated. * Learn more about the COVID-19 vaccines and rare serious allergic reactions.
* If you have had a severe allergic reaction to other vaccines or injectable therapies, ask your doctor if you should receive Moderna's vaccine. Your doctor will help you determine if it is safe to receive the Moderna vaccine.
Side effects and safety
In the arm where you received the injectable vaccine:
- Pain
- Swelling
- Redness
In the rest of the body:
- Shaking chills
- Fatigue
- Headache
These side effects usually appear within a day or two after getting vaccinated. They can look like flu symptoms and may even affect your ability to do daily activities, but they should go away in a few days.
Information on the effectiveness of the vaccine
Based on evidence from clinical trials, Moderna's vaccine was shown to be 94.1% effective in preventing laboratory-confirmed COVID-19 cases in people who received two doses and who had no evidence of previous infections.
Demographic information from clinical trials
LThe clinical trials for Moderna's vaccine included people from the following racial and ethnic categories:
- 79,4 % white
- 20 % Hispanic / Latino people
- 9,7 % African American
- 4,7 % Asian
- < 3 % of people of other races/ethnicities
Breakdown by age and sex:
- 52,6 % men
- 47,4 % women
- 25,3 % 65 years of age or older
The majority of people who participated in the trials (82%) were considered to be at risk of occupational exposure, while 25.4% of them were healthcare workers.
Of the people who participated in clinical trials, 22.3% had at least one high-risk condition, which included lung disease, heart disease, obesity, diabetes, liver disease, or HIV. Four percent (4%) of the participants had two or more high-risk conditions.